Resumen

Cutaneous aspergillosis is very rare and occurs predominantly in immunocompromised patients including transplant recipients. We report a 26-year-old male with acute lymphoblastic leukemia who developed cutaneous aspergillosis after undergoing combined immunosuppressive treatment including corticosteroid, cyclosporine A, mychophenolate mofetil and mesenchymal stem cells for steroid refractory skin acute graft versus host disease after myeloablative haematopoietic stem cell transplantation. The patient was treated with oral voriconazole therapy and recovered partially.

Palabras clave: Haematopoietic stem cell transplantation; graft versus host disease; mesenchymal stem cells; cutaneous aspergillosis.

2013-02-05   |   314 visitas   |   Evalua este artículo 0 valoraciones

Vol. 5 Núm.5. Mayo 2011 Pags. 406-409 J Infect Developing Countries 2011; 5(5)